1National Committee for Clinical Laboratory Sandards. Perfomance standards for antimicrobial susceptibility tests. Fourteenth informational supplement [ S ]. 2003NCCLS M100 - S13( M7 ) ,2003:20 - 54.
2Koeppe P, Hoffler D, Strobel K. Pharmacokinetics and dose recommendations of carumonam in renal failure[J]. Arzneimittelforschung, 1987;37:65 - 69.
3Fillastre JP, Leroy A, Baudoin C. Pharmacokinetics of aztreonam in patients with chronic renal failure [ J] . Clin Pharmacokinet, 1985; 10:91 - 100.
4Yan JJ, Hsueh PR, Kowc, et al. Metallo - beta - lactamases in clinical pseudomonas isolates in Taiwan and identification of VIM - 3 , a novel variant of the VIM - 2 enzyme [ J ]. Antimicrob Agents Chemother,2001 ;45:2224 - 2228.
5何札贤.抗生素时代肺炎问题一瞥[J].中华医学杂志,1999,20(4):2-2.
6Duma RJ. Microbiology and pharmacology of aztreonam[J]. Urology, 1998, 31(Suppl 6): 9-13
7Fekete T, Castellano M, Ramirez J, et al. A randomized comparative trial of aztreonam plus cefazolin versus ceftazidime for the treatment of nosocomial pneumonia[J]. Drug Invest, 1994, 7(3): 117-126
8Brogden RN, Heel RC. Aztreonam: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use[J]. Drugs, 1986, 31(2): 96-130
